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Flt1/VEGFR1 heterozygosity causes 
transient embryonic edema
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Shigenobu Yonemura3, Masabumi Shibuya4, Janet Rossant5, Toshio Suda6,7, Yoshihiro Kakeji2 
& Masanori Hirashima1
Vascular endothelial growth factor-A is a major player in vascular development and a potent vascular 
permeability factor under physiological and pathological conditions by binding to a decoy receptor Flt1 
and its primary receptor Flk1. In this study, we show that Flt1 heterozygous (Flt1+/−) mouse embryos 
grow up to adult without life-threatening abnormalities but exhibit a transient embryonic edema 
around the nuchal and back regions, which is reminiscent of increased nuchal translucency in human 
fetuses. Vascular permeability is enhanced and an intricate infolding of the plasma membrane and 
huge vesicle-like structures are seen in Flt1+/− capillary endothelial cells. Flk1 tyrosine phosphorylation 
is elevated in Flt1+/− embryos, but Flk1 heterozygosity does not suppress embryonic edema caused 
by Flt1 heterozygosity. When Flt1 mutants are crossed with Aspp1−/− mice which exhibit a transient 
embryonic edema with delayed formation and dysfunction of lymphatic vessels, only 5.7% of 
Flt1+/−; Aspp1−/− mice survive, compared to expected ratio (25%). Our results demonstrate that Flt1 
heterozygosity causes a transient embryonic edema and can be a risk factor for embryonic lethality in 
combination with other mutations causing non-lethal vascular phenotype.
Vascular endothelial growth factor (VEGF)-A is a major player in all aspects of vascular development and is also 
a potent vascular permeability factor that is involved in fluid homeostasis under physiological and pathological 
conditions1–3. VEGF-A works through receptor tyrosine kinases expressed in endothelial cells, Flt1 and Flk1, 
which are also called VEGFR1 and VEGFR2, respectively4. Gene-targeting studies established that Flt1 serves 
mainly as a decoy receptor to sequester VEGF-A from activating the other primary receptor Flk1 in vascular 
development5–8. Interestingly, VEGF-A haploinsufficiency in mice resulted in embryonic lethality associated with 
defective blood vessel development9,10, whereas a hypermorphic allele of VEGF-A gene produced severe abnor-
malities in heart development and embryonic lethality11, indicating that a subtle change of VEGF-A protein 
levels affects vascular function during mouse embryogenesis. Although local concentration of VEGF-A protein 
is regulated by a decoy receptor Flt1, it has not been addressed whether Flt1 heterozygosity affects embryonic 
development.
The lymphatic vascular system functions in concert with the blood vascular system to regulate the tissue fluid 
homeostasis of the body. Most of the extravasated interstitial fluid is absorbed back into the blood capillaries, 
whereas the remaining fluid and macromolecules are taken up and transported to venous circulation by lym-
phatic vessels. Dysfunction or impaired development of lymphatic vessels causes lymphedema12–14. We previously 
reported that loss of Aspp1, a p53-binding protein predominantly expressed in endothelial cells, causes embry-
onic edema with defective lymphatic development in mice15–17.
In this study, we investigated Flt1 heterozygous (Flt1+/−) mice to determine the regulatory role of Flt1 in vas-
cular development and fluid homeostasis since the homozygotes are embryonic lethal with a defect in early blood 
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vessel development5. Here, we show that Flt1 heterozygosity causes embryonic edema with enhanced vascular 
permeability. We also show that Flt1 heterozygosity can be a risk factor for embryonic lethality in combination 
with other mutations causing non-lethal vascular phenotype.
Results and Discussion
Flt1+/− mice showed a transient embryonic edema without overt defects in cardiovascular 
development. Of 263 embryos from mating wild-type (WT) female with Flt1+/− male mice, the expected 
ratio of genotypes was observed at embryonic day (E) 14.5 (WT 49.0%, Flt1+/− 51.0%). We found that Flt1+/− 
embryos exhibit edema around the nuchal and back regions from E13.5 till E17.5, compared to WT embryos 
(Fig. 1A–C, data not shown), while edema resolves by birth. Western blot analysis using embryonic back skin 
shows an increased level of Flk1 tyrosine phosphorylation in Flt1+/− embryos (Fig. 1D,E). On the other hand, 
Figure 1. Flt1+/− mice showed a transient embryonic edema without overt defects in vascular 
development. (A,B) Lateral view of whole-mount embryos at E14.5 from crosses between WT and Flt1+/− 
mice. Subcutaneous edema (arrowheads) is observed only in Flt1+/− embryos. (C) The edema index of Flt1+/− 
embryos is significantly higher than WT embryos (WT, n = 21; Flt1+/−, n = 16). (D,E) Western blot analysis 
using embryonic back skin at E14.5 shows the levels of Flk1 tyrosine phosphorylation are elevated in Flt1+/− 
embryos, compared to WT embryos (n = 3 each group). (F–K) Immunofluorescence confocal microscopic 
images of flat-mount embryonic back skin at E15.5 stained for PECAM-1 (red) and Flt4 (green). (L) Number 
of capillary branching points (per mm2) (n = 3 each group). (M) Blood vessel density (vessel area/total area of 
interest). There was no significant difference in blood and lymphatic vascular network between WT and Flt1+/− 
embryos (n = 3 each group). Data are presented as mean ± standard error of the mean. * * * P < 0.001 and  
* P < 0.05 as determined by unpaired two-tailed Student’s t-test. N.S. = not significant.
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when we analyzed mice harboring a Flt1TK mutant allele lacking the tyrosine kinase domain but bearing an 
intact extracellular domain for VEGF-A sequestration7, edema was not detected in Flt1+/TK or Flt1TK/TK embryos 
(Supplementary Fig. S1). These results indicate that reduction in VEGF-A sequestration rather than Flt1 signals 
affects fluid homeostasis in mouse embryos.
To clarify the causes of embryonic edema in Flt1+/− embryos, we investigated cardiovascular development. 
Expression analysis using mice carrying a β -galactosidase reporter knocked into the Flt1 or Flk1 locus and blood 
endothelial cells (BECs) and lymphatic endothelial cells (LECs) isolated from embryonic back skin showed that 
Flt1 is expressed in BECs but not in LECs, whereas Flk1 is expressed in both endothelial cell types (Supplementary 
Fig. S2). Whole-mount immunostaining of the back skin for a pan-endothelial marker PECAM-1 and a LEC 
marker Flt4 (also called VEGFR3) showed that network formation of blood and lymphatic vessels is comparable 
between WT and Flt1+/− embryos at E15.5 (Fig. 1F–M and Supplementary Fig. S3). The compact layers of ventri-
cles, trabeculation, and interventricular septum that are defective in VEGF-A-overexpressing embryos11 are also 
normal in Flt1+/− embryos (Supplementary Fig. S4).
Flt1+/− embryos showed enhancement of vascular permeability with huge vesicle-like struc-
tures in capillary endothelial cells. To look further for the causes of embryonic edema in Flt1+/− embryos, 
we next investigated vascular permeability by assessing the leakage of Hoechst 33258 injected into blood vessels of 
embryos from crosses between WT and Flt1+/− mice. Nuclei of BECs alone were stained in WT embryos, whereas 
those of tissues surrounding blood vessels were stained by Hoechst 33258 leaked out of blood vessels in Flt1+/− 
embryos, indicating enhancement of vascular permeability (Fig. 2A–C). Since edema in Flt1+/− mice is tran-
sient during mid-gestation and is not detected after birth, we performed vascular permeability in adult mice by 
Figure 2. Flt1+/− embryos showed enhancement of vascular permeability with huge vesicle-like structures 
in capillary endothelial cells. (A–C) Vascular permeability assay in E14.5 embryos. Frozen sagittal sections 
show the nuclei of BECs alone in WT embryos and those of surrounding tissues in Flt1+/− embryos following 
intravenous injection of Hoechst 33258 (n = 6 each group). (D–J) Transmission electron microscopic images of 
capillaries in WT and Flt1+/− embryonic back skin at E14.5. Endothelial cells of the blood capillaries containing 
erythrocytes (e) have an intricate intricate infolding of the plasma membrane and more huge vesicle-like 
structures (asterisks) which sometimes reach the lateral plasma membrane where adherens junctions reside 
(H, arrowheads) or are connected to the vascular lumen ((I,J) arrow in adjacent sections) in Flt1+/− embryos. 
(K) Number of vesicle-like structures in capillary endothelial cells (n = 6 each group). Data are presented as 
mean ± standard error of the mean. * * * P < 0.001 and * * P < 0.01 as determined by unpaired two-tailed Student’s 
t-test. N.S. = not significant.
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Figure 3. Flt1 heterozygosity enhances embryonic edema in Aspp1−/− embryos. (A–D) Lateral view of 
whole-mount embryos at E14.5 from crosses between Flt1+/−; Aspp1+/− and Aspp1−/− mice. Subcutaneous 
edema (arrowheads) is detected in all embryos except Aspp1+/− embryos. Flt1 heterozygosity greatly enhances 
edema in Aspp1−/− embryos. (E–H) Immunofluorescence confocal microscopy images of flat-mount embryonic 
back skin at E15.5 stained for PECAM-1 (red) and Flt4 (green). Partly-distended lymphatic vessels and 
lymphatic islands (arrowheads) are detected in mice carrying Aspp1−/− mutation. (I–L) Vascular permeability 
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assessing the leakage of intravenously-injected Evans blue dye after topical application of mustard oil. This analysis 
showed that vascular permeability is comparable between WT and Flt1+/− adult mice (Supplementary Fig. S5), 
suggesting that the enhancement of vascular permeability is restricted to embryonic development in Flt1+/− mice.
It has been shown that VEGF-A induces vascular permeability by regulating paracellular and transcellular 
transports in endothelial cells18. VEGF-A activates Src pathway leading to loosening of endothelial cell-to-cell 
junctions19–22, and an in vivo injection of VEGF-A induces the formation of vesiculo-vacuolar organelles23. To 
address the cellular basis of enhanced vascular permeability in Flt1+/− embryos, we investigated VE-cadherin, 
Claudin-5, and β -catenin proteins, components of adherens junction or tight junction, but their staining pat-
terns do not appear different between WT and Flt1+/− embryos (Supplementary Fig. S6). Western blot analysis 
using embryonic back skin showed that Src activity assessed by Y416 phosphorylation (Src-pY416) is compa-
rable between WT and Flt1+/− embryos (Supplementary Fig. S7). Loss of pericyte coverage is also known to 
correlate with enhanced vascular permeability24–26, but immunostaining of a pericyte marker Desmin together 
with PECAM-1 showed that pericyte coverage of capillary blood vessels is not affected in Flt1+/− embryos 
(Supplementary Fig. S8). Transmission electron microscopic analysis showed an intricate infolding of the 
plasma membrane and more huge vesicle-like structures in Flt1+/− blood capillary endothelial cells (Fig. 2D–K). 
Vesicle-like structures sometimes reach the lateral plasma membrane where adherens junctions reside or are con-
nected to the vascular lumen in Flt1+/− embryos (Fig. 2H–J). These morphological changes in endothelial cells are 
most likely related to the enhanced vascular permeability in Flt1+/− embryos although it remains to be elucidated 
whether paracellular and/or transcellular transports are involved.
Flk1 heterozygosity does not suppress embryonic edema caused by Flt1 heterozygosity. Flk1 
is the primary receptor for VEGF-A and its tyrosine phosphorylation is elevated in Flt1+/− embryos. To investi-
gate whether Flk1 heterozygosity suppresses embryonic edema caused by Flt1 heterozygosity, we crossed Flt1+/− 
and Flk1+/− mice. Flt1+/−; Flk1+/− and Flt1+/− embryos exhibited a comparable edema although Flk1+/− embryos 
appeared normal (Supplementary Fig. S9). In addition to embryonic edema, Flt1+/−; Flk1+/− mice surprisingly 
showed buphthalmia caused by abnormal aqueous humor homeostasis, as we reported previously27. Although 
Flk1+/− mice do not exhibit embryonic edema or buphthalmia, it will be intriguing to look further into subtle 
vascular defects of Flk1+/− mice in the future.
Flt1 heterozygosity promotes death of Aspp1−/− embryos. We previously reported that Aspp1−/− 
mice exhibit a transient embryonic edema with delayed formation and dysfunction of lymphatic vessels in 
embryos. The edema resolves by birth, and no overt abnormalities have been detected in adults17. Similarly, 
Flt1+/− mice grow up normally to adult without life-threatening abnormalities, despite a transient embryonic 
edema caused by enhanced vascular permeability. To test whether dysregulation of fluid homeostasis may 
influence the viability of mouse embryos, we crossed these two mutants and analyzed occurrence and extent of 
edema, vascular formation, vascular permeability, and survival rate of their offspring. When we crossed Flt1+/−; 
Aspp1+/− mice and Aspp1−/− mice, all embryos except Aspp1+/− embryos showed edema at E14.5 (Fig. 3A–D,M). 
Flt1 heterozygosity greatly enhanced edema in Aspp1−/− embryos. Moreover, only 5.7% of all offspring was 
Flt1+/−; Aspp1−/− at weaning, which is significantly lower than the predicted Mendelian frequency (25%) 
(Table 1A). We did not notice any loss of pups during the postnatal periods between birth and weaning, suggest-
ing that loss of Flt1+/−; Aspp1−/− mice during embryogenesis is critical. Whole-mount immunostaining of the 
back skin for PECAM-1 and Flt4 showed that partly-distended lymphatic vessels and lymphatic islands, both of 
which are a characteristic of Aspp1−/− embryos, are detected in mice carrying the Aspp1−/− mutation (Fig. 3E–H). 
On the other hand, vascular permeability assessed by Hoechst 33258 injection is enhanced in mice carrying 
the Flt1+/− mutation (Fig. 3I–L,N). When Aspp1 mutants were crossed with Flt1TK mutants, Flt1+/TK; Aspp1−/− 
mice survived to adult at a normal Mendelian frequency (Table 1B). These results suggest that both lymphatic 
dysfunction and enhanced vascular permeability are responsible for stronger edema formation and lethality of 
Flt1+/−; Aspp1−/− embryos. They have been reported that Src plays a role in VEGF-A-induced vascular permea-
bility19–22 and that ASPP and Src play a cooperative role in epithelial organization in Drosophila28. Western blot 
analysis using embryonic back skin from mating between Flt1+/−; Aspp1+/− mice and Aspp1−/− mice showed 
that Src-pY416 is elevated in Flt1+/−; Aspp1−/− mice but not in other littermates including Flt1+/−; Aspp1+/− and 
Aspp1−/− mice (Fig. 3O,P). This result suggests a synergistic regulation of Src by VEGF-A and Aspp1 although a 
detailed mechanism remains to be addressed.
In contrast to a reduction of Flt1 causing a transient embryonic edema, it has been reported that elevated 
levels of circulating soluble Flt1 are associated with preeclampsia in humans, a severe complication of pregnancy 
involving maternal hypertension, proteinuria and glomerular malfunction29. Taken together, a fine tuning of fluid 
homeostasis by a balance between VEGF-A and decoy receptor Flt1 is crucial for proper embryonic development 
assay in E14.5 embryos. Frozen sagittal sections show the nuclei of surrounding tissues as well as BECs in mice 
carrying Flt1+/− but not Aspp1−/− mutation following intravenous injection of Hoechst 33258. (M) The edema 
index of Flt1+/−; Aspp1+/−, Aspp1−/− and Flt1+/−; Aspp1−/− embryos are significantly higher than Aspp1+/− 
embryos (Aspp1+/−, n = 6; Flt1+/−; Aspp1+/−, n = 4; Aspp1−/−, n = 8; Flt1+/−; Aspp1−/−, n = 3). (N) Vascular 
permeability is enhanced with mice carrying Flt1+/− mutation (n = 3 each group). (O,P) Western blot analysis 
using embryonic back skin at E14.5 shows that Src activity is elevated in Flt1+/−; Aspp1−/− mice but not in  
other littermates (n = 3 each group). Data are presented as mean ± standard error of the mean. * * * P < 0.001,  
* * P < 0.01 and * P < 0.05 as determined by one-way analysis of variance for inter-group comparisons, and 
Tukey-Kramer method for group comparisons. N.S. = not significant.
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and maternal health. These results also suggest that alterations in Aspp1 or Flt1 function could underlie the tran-
sient increase in nuchal translucency observed in some human fetuses, a defect that can still be compatible with 
a normal pregnancy outcome30,31. However, combined defects in pathways affecting vascular permeability and 
lymphatic drainage could lead to fetal loss.
Materials and Methods
Mice. A colony of mice heterozygous for Flt1+/lacZ, Flk1+/lacZ, Flt1+/TK, or Aspp1+/lacZ was maintained as 
described previously7,17,32. Noon of the day on which the vaginal plug was detected was considered as E0.5. 
Embryos were genotyped by PCR analysis of tail DNA. Animal experiments were approved by the Institution 
Animal Care and Use Committee of Kobe University Graduate School of Medicine, and carried out in accordance 
with the animal experimentation guidelines of the Kobe University Graduate School of Medicine.
Measurement of embryonic edema. Digital images of embryo propers were acquired with illumination 
from the bottom under dissecting microscope, and the number of pixels for a transparent area of embryos and 
crown-rump length (CRL) was measured. The extent of embryonic edema was examined as an edema index, 
which is a transparent area divided by the square of CRL.
Western blot analysis. Whole embryos were dissected at E14.5, and the back skin was peeled off and lysed 
in 50 mmol/L Tris-HCl (pH7.4) containing 1% Triton X-100, 150 mmol/L NaCl, 10% glycerol, 1.5 mmol/L MgCl2, 
1 mmol/L phenylmethylsulfonyl fluoride, 20 mmol/L NaF, 10 mmol/L Na4P2O7, 2 mmol/L Na3VO4, protease 
inhibitor cocktail, and phosphatase inhibitor. After 30 min incubation at 4 °C, the lysate was clarified by centrifu-
gation at 10000 g for 15 min at 4 °C. The supernatant containing equal amounts of protein was used as samples for 
immunoprecipitation, SDS-PAGE, and western blot on PVDF membranes with antibodies to Src and Src-pY416. 
For detection of total and phosphorylated Flk1, Flk1 proteins were collected from the lysate by immunoprecipita-
tion with anti-Flk1 antibody (clone 55B11), followed by western blot with antibodies to Flk1 or phospho-tyrosine 
(clone PY20). We used horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG as secondary anti-
bodies and enhanced chemiluminescence for detection with LAS-1000 (Fujifilm). To quantitate phosphorylated 
protein per total protein, the densitometric analysis of digital images was performed using the ImageJ software 
(National Institutes of Health).
Immunohistochemistry. We used goat anti-Flt4, rat anti-PECAM-1 (clone Mec13.3), Armenian hamster 
anti-PECAM-1 (clone 2H8), rat anti-LYVE-1 (clone ALY7)33, rabbit anti-β -galactosidase, rat anti-VE-cadherin 
(clone 11D4.1), mouse anti-Claudin-5 (clone 4C3C2), rabbit anti-β -catenin, goat anti-Flk1, and mouse 
anti-Desmin (clone D33) antibodies. For immunofluorescence, we used Alexa Fluor 488-, Cy3-, or Cy5-conjugated 
secondary antibodies.
For immunohistochemical analysis of embryonic back skin, whole embryos were dissected at E14.5 and E15.5 
and fixed in phosphate-buffered saline (PBS) containing 4% paraformaldehyde at 4 °C for 10 minutes. The back 
skin was peeled off and further fixed in the same fixative at 4 °C for 3 hours. Tissues were washed in PBS with 0.2% 
Triton X-100 (PBT) at 4 °C for 30 minutes twice, blocked in PBT containing 1% bovine serum albumin at room 
temperature for 1 hour, and stained with primary antibodies in blocking solution at 4 °C overnight. Tissues were 
washed in PBT for 30 minutes 3 times at 4 °C and twice at room temperature, followed by staining with secondary 
antibodies in blocking solution at 4 °C overnight. Tissues were washed in PBT for 30 minutes 3 times at 4 °C and 
twice at room temperature. Back skin was flat-mounted on slide glasses in ProLong Antifade and analyzed by 
confocal laser scanning microscopy (FV-1000, Olympus or LSM 700, Zeiss). Quantification of pericyte coverage 
was measured on the number of pixels of PECAM-1+ blood vessels and Desmin+ pericytes.
(A) Number of live mice from crosses of Flt1+/−; Aspp1+/− and Aspp1−/− mice
Stage Litter no. Aspp1+/− Flt1+/−; Aspp1+/− Aspp1−/− Flt1+/−; Aspp1−/− Total P-value
E13.5 (%) 1 7 (46.6) 3 (20.0) 4 (26.7) 1 (6.7) 15 N.S.
E14.5 (%) 12 33 (24.8) 31 (23.3) 37 (27.8) 24 (18.1) 125 N.S.
2 (1.5)† 6 (4.5)† 8†
E15.5 (%) 4 18 (33.3) 11 (20.4) 9 (16.6) 11 (20.4) 49 N.S.
1 (1.9)† 4 (7.4)† 5†
E16.5 (%) 1 1 (16.7) 3 (50.0) 0 (0) 2 (33.3) 6 N.S.
E17.5 (%) 5 11 (20.4) 19 (35.2) 14 (25.9) 3 (5.5) 47 N.S.
7 (13.0)† 7†
At weaning (%) 56 158 (36.2) 130 (29.8) 123 (28.2) 25 (5.8) 436 < 0.001
Expected (%) (25) (25) (25) (25)
(B) Number of live mice from crosses of Flt1+/TK; Aspp1+/− and Aspp1−/− mice
Stage Litter no. Aspp1+/− Flt1+/TK; Aspp1+/− Aspp1−/− Flt1+/TK; Aspp1−/− Total P-value
At weaning (%) 35 109 (29.8) 83 (22.7) 80 (21.8) 94 (25.7) 366 N.S.
Expected (%) (25) (25) (25) (25)
Table 1.  Heterozygosity of Flt1 knockout allele but not of Flt1TK allele promotes death of Aspp1−/− mice. 
†Embryos found dead at dissection is indicated.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:27186 | DOI: 10.1038/srep27186
Vascular permeability assay. Embryos were recovered with intact yolk sac and placenta at E14.5, per-
fused individually with Hoechst 33258 (2 μ g/embryo) from the vitelline vein for 5 minutes, and dissected further 
to collect the embryo propers. The embryos were mounted in OCT compound and cut sagittally in 10 μ m thick 
cryosections. The distribution of stained nuclei was examined by inverted fluorescent microscopy (IX81, 
Olympus). The extent of vascular permeability of dermal blood vessels was measured as the number of stained 
nuclei per total cell number in a circular area of 20000 μ m2.
Adult mice at 6 to 7 weeks of age were anesthetized and injected with Evans blue dye (30 mg/kg in 300 μ l) 
into a tail vein. After 1 minute, 5% mustard oil in mineral oil was applied to the dorsal and ventral surfaces of the 
ear with a cotton tip. After 30 minutes, mice were perfused with 10 ml of PBS containing 1% paraformaldehyde 
to wash out dye from blood vessels. Ears were removed, dried at 55 °C overnight, and weighed. Evans blue was 
extracted from the ears in 1 ml of formamide at 55 °C overnight and measured with spectrophotometry at OD610. 
The standard curve was prepared from serial dilutions of Evans blue dye at known concentration in formamide 
and used to determine the concentration in samples. The extent of vascular permeability was measured as the 
weight of extracted dye per weight of ear34. We analyzed one ear per mouse.
Transmission electron microscopic analysis. Trunk of embryos was fixed in 0.1 M cacodylate buffer 
(pH7.4) containing 2% paraformaldehyde and 2% glutaraldehyde at room temperature for 2 hours and at 4 °C 
overnight. After the fixation, the samples were postfixed in 1% osmium tetroxide in the same buffer for 1 hour 
on ice, dehydrated in a series of graded ethanol, and embedded in resin. Thin sections were cut with an ultrami-
crotome (ULTRACUT, Leica) and examined in an electron microscope (JEM-1010, JEOL Ltd.).
Reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was isolated by an RNeasy 
Mini Kit and RNase-Free DNase Set from PECAM-1+/LYVE-1−/CD45− BECs and PECAM-1+/LYVE-1+/
CD45− LECs purified from the back skin at E14.5, as described previously17. First-strand cDNA was synthe-
sized using the Super Script first-strand synthesis system for RT-PCR according to the manufacturer’s instruc-
tions, and used for PCR analysis with specific primers for Flt1 (5′ -TGTGGAGAAACTTGGTGACCT-3′ 
and 5′ -TGGAGAACAGCAGGACTCCTT-3′ ), Flk1 (5′ -AGAACACCAAAAGAGAGGAACG-3′ and 5′ 
-GCACACAGGCAGAAACCAGTAG-3′ ), PECAM-1 (5′ -CAAACCGTATCTCCAAAGCC-3′ and 5′ 
-TCTGTGAATGTTGCTGGGTC-3′ ), LYVE-1 (5’-TTCCTCGCCTCTATTTGGAC-3′ and 5′ -ACGGGGTAA 
AATGTGGTAAC-3 ′  ) ,  Prox1 (5 ′  -AAGTGGT TCAGCAAT T TCCG-3 ′   and 5 ′  -TGACCT TGT 
AAATGGCCTTC-3′ ) and β -actin (5′ -GGACTCCTATGTGGGTGACGAGG-3′ and 5′ -GGGAGA 
GCATAGCCCTCGTAGAT-3′ ).
Hematoxylin and Eosin (H&E) staining. E14.5 embryos were fixed in PBS containing 4% paraformalde-
hyde at 4 °C overnight, dehydrated into methanol, embedded in paraffin, cut in 5 μ m thick sections, and stained 
with H&E by standard procedures.
Statistical analysis. Values are presented as mean ± standard error of the mean. The unpaired two-tailed 
Student’s t-test was used to compare the results between two groups. One-way analysis of variance was used for 
inter-group comparisons, and Tukey-Kramer method was used for group comparisons. Chi-square test was per-
formed to compare the actual survival to expected numbers. At least three specimens were analyzed in all cases. 
P-values are indicated as follows; * * * P < 0.001, * * P < 0.01, and * P < 0.05.
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